Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Growth hormone

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    573 result(s) found for: Growth hormone. Displaying page 6 of 29.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next» Last»»
    EudraCT Number: 2014-004160-38 Sponsor Protocol Number: 93-8122-001 Start Date*: 2015-04-01
    Sponsor Name:KABI PHARMACIA S.A.
    Full Title: A 2 Year Multicenter Study of Genotropin Treatment of Short Prepubertal Children with Intra-Uterine Growth Retardation
    Medical condition: Growth Disorders, Intrauterine Growth Retardation
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2021-001624-17 Sponsor Protocol Number: 210321 Start Date*: 2021-07-21
    Sponsor Name:Karolinska University Hospital
    Full Title: Safety of oral micronized progesterone versus norethisterone acetate in continuous combination with oral estrogen as menopausal hormone therapy – a double-blind randomized study- PROBES study (Prog...
    Medical condition: Climacteric symptoms
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-004304-39 Sponsor Protocol Number: A6281283 Start Date*: 2008-03-12
    Sponsor Name:Pfizer Pharma GmbH
    Full Title: NEUROMUSCULAR CHANGES IN SMALL FOR GESTATIONAL AGE (SGA-) CHILDREN DURING SOMATROPIN THERAPY - A PROSPECTIVE, RANDOMIZED, CONTROLLED, OPEN-LABEL, MULTICENTER TRIAL (SGA-POWER STUDY)
    Medical condition: Growth disturbance (current height SDS < -2.5 and parental adjusted height SDS < -1) in short children born small for gestational age (SGA), with a birth weight and/or length below -2 SD, who faile...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10041093 Small for gestational age LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-002912-10 Sponsor Protocol Number: CH-ACM-01 Start Date*: 2011-08-31
    Sponsor Name:Chiasma, Inc.
    Full Title: EFFICACY AND SAFETY OF ORAL OCTREOLIN™ IN PATIENTS WITH ACROMEGALY WHO ARE CURRENTLY RECEIVING PARENTERAL SOMATOSTATIN ANALOGS
    Medical condition: Acromegaly
    Disease: Version SOC Term Classification Code Term Level
    16.0 10014698 - Endocrine disorders 10000599 Acromegaly PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) NL (Completed) GB (Completed) DE (Completed) SK (Completed) PL (Completed) IT (Completed) SI (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2015-001708-69 Sponsor Protocol Number: 20184 Start Date*: 2015-07-15
    Sponsor Name:Merck KGaA
    Full Title: An Open Study of the Safety and Efficacy of Saizen®, (Recombinant Human Growth Hormone, r-hGH), in Children Born With Serious Intra-uterine Growth Retardation (IUGR) Treated to Final Height
    Medical condition: Children Born With Serious Intra-uterine Growth Retardation
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2019-002193-31 Sponsor Protocol Number: CRN00808-05 Start Date*: 2020-02-19
    Sponsor Name:Crinetics Pharmaceuticals, Inc.
    Full Title: AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CRN00808 IN SUBJECTS WITH ACROMEGALY (ACROBAT ADVANCE)
    Medical condition: Acromegaly is typically caused by a growth hormone (GH) secreting tumor in the pituitary. Excess GH secretion results in excess secretion of insulin-like growth factor-1 (IGF-1) from the liver, whi...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10000599 Acromegaly PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Trial now transitioned) SK (Completed) GR (Trial now transitioned) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-003327-23 Sponsor Protocol Number: IP107-001 Start Date*: 2008-10-29
    Sponsor Name:Endo Pharmaceuticals Solutions Inc
    Full Title: PHASE III, OPEN-LABEL, MULTICENTER INTERNATIONAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AN OCTREOTIDE IMPLANT VERSUS SANDOSTATIN LAR® DEPOT IN PATIENTS WITH ACROMEGALY
    Medical condition: Acromegaly
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000599 Acromegaly LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) PL (Completed) DE (Completed) ES (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2009-010288-17 Sponsor Protocol Number: 1516 Start Date*: 2009-07-13
    Sponsor Name:Karolinska Hospital
    Full Title: Breast cell turnover and mammographic density in women with Polycystic Ovary Syndrome (PCOS)
    Medical condition: Polycystic ovary syndrome (PCOS) is the most common hormonal aberration in women of fertile age, with a prevalence of 5-10%, and is associated with chronic anovulation, hyperandrogenism and PCO mo...
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-000831-34 Sponsor Protocol Number: GoforGH Start Date*: 2022-01-11
    Sponsor Name:Medical University of Vienna
    Full Title: InvestiGating the rOle of Growth Hormone in hepatic lipid metabolism in humans
    Medical condition: Healthy subjects
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-001574-24 Sponsor Protocol Number: 13041970 Start Date*: 2006-10-06
    Sponsor Name:Radboud University Nijmegen Medical Centre, Department of Endocrinology
    Full Title: Visualisation of coronary arteries for the analysis of premature atherosclerosis in patients with adult-onset GH deficiency
    Medical condition: Patients with adult-onset growth hormone deficiency and the presence of atherosclerotic disease in the coronary arteries
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2012-000814-13 Sponsor Protocol Number: ML7981 Start Date*: 2012-03-16
    Sponsor Name:University Hospital Leuven
    Full Title: Glibenclamide treatment in hypotonia-cystinuria syndrome
    Medical condition: Hypotonia-cystinuria syndrome/PREPL deficiency
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2004-004781-33 Sponsor Protocol Number: A6281273 Start Date*: 2005-07-13
    Sponsor Name:Pfizer Pharma GmbH
    Full Title: Somatropin Therapy for Short Children Born of Premature Gestation: A Controlled, Prospective Randomized, Multicenter Study with an Untreated Control Group
    Medical condition: Short children born of premature gestation
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2022-002471-11 Sponsor Protocol Number: Leuprorelin-4002 Start Date*: 2022-08-08
    Sponsor Name:Takeda (China) International Trading Co., Ltd.
    Full Title: An Open Label, Multicenter, Single-arm and Prospective Study to Assess the Efficacy and Safety of Leuprorelin 3M in the Treatment of Central Precocious Puberty (CPP)
    Medical condition: Central Precocious Puberty
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004860 10073186 Central precocious puberty LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2008-002338-31 Sponsor Protocol Number: 47 Start Date*: 2008-08-29
    Sponsor Name:Hannover Medical School
    Full Title: Prospektive randomisierte Phase II Studie zur Behandlung von Patienten mit fortgeschrittenem hormonrefraktären Prostatakarzinom mittels LHRH-Analoga und Somatostatin-Analoga unter Berücksichtigung ...
    Medical condition: Patients with hormone - independent non metastatic prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10062904 Hormone-refractory prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-005313-39 Sponsor Protocol Number: LAN-HD-ACRO Start Date*: 2013-05-17
    Sponsor Name:AZIENDA OSPEDALIERA Spedali Civili di Brescia
    Full Title: Scheme of treatment with high-dose lanreotide in acromegalic patients poorly responsive to treatment with standard doses."
    Medical condition: acromegaly
    Disease: Version SOC Term Classification Code Term Level
    14.1 10014698 - Endocrine disorders 10000599 Acromegaly PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-004386-24 Sponsor Protocol Number: PEGACRO Start Date*: 2015-12-04
    Sponsor Name:DIPARTIMENTO DI MEDICINA CLINICA E CHIRURGIA - UNIVERSITÀ DEGLI STUDI DI NAPOLI FEDERICO II
    Full Title: Effect of GH receptor antagonist on insulin resistance associated with acromegaly
    Medical condition: acromegaly
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10000599 Acromegaly PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-004356-20 Sponsor Protocol Number: DCS-002 Start Date*: 2011-10-31
    Sponsor Name:Pergamum AB
    Full Title: A randomised, parallel-group, double-blind, placebo-controlled study of DPK-060 to investigate clinical safety and efficacy in patients with acute external otitis
    Medical condition: Acute external otitis (EO)
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-002228-34 Sponsor Protocol Number: 2012/1vas Start Date*: 2015-09-30
    Sponsor Name:Diego Caicedo Valdés
    Full Title: Growth hormone (GH) angiogenic effect clinical trial on patients with lower limb critical ischemia. GHAS Study
    Medical condition: Lower limb critical ischemia
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004866 10023034 Ischemia peripheral LLT
    18.0 100000004866 10058069 Critical limb ischemia LLT
    18.0 100000004866 10066920 Leg ischemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-004172-32 Sponsor Protocol Number: A6281280 Start Date*: 2015-04-01
    Sponsor Name:Pfixer Inc
    Full Title: A Four-Year Open-Label Multi-Center Randomized Two-Arm Study of Genotropin in Idiopathic Short Stature Subjects: Comparing an Individualized, Target-Driven Treatment Regimen to Standard Dosing of G...
    Medical condition: Idiopathic short stature (ISS)
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2004-002849-12 Sponsor Protocol Number: CSOM230B2201E1 Start Date*: 2005-01-12
    Sponsor Name:Novartis Pharmaceuticals UK Ltd
    Full Title: Extension to a multicenter, randomized, crossover, open label, dose finding study to compare the safety, efficacy and PK/PD relationship of multiple doses of SOM230 (200, 400 and 600 µg b.i.d.) and...
    Medical condition: Acromegaly is a rare, serious condition characterized by chronic hypersecretion of GH (growth hormone) caused in over 95% of patients by a GH-secreting pituitary adenoma. Clinical manifestations ar...
    Disease: Version SOC Term Classification Code Term Level
    7.0 10000599 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) IT (Completed) ES (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 31 09:32:59 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA